Austar Lifesciences (HKG:6118) expects a profit attributable to the owners between 15 million yuan and 20 million yuan in 2024, against an attributable loss of 113 million yuan logged for 2023, a Monday Hong Kong bourse filing said.
The company attributed the turnaround to a lack of loss from subsidiaries compared with a year ago, an increase in other income, and the group's organizational optimization.
Shares of the company closed nearly 2% higher on Tuesday.
Price (HKD): $0.57, Change: $+0.0100, Percent Change: +1.79%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.